Related Experiment Videos
Sequential high dose-density chemotherapy with two active regimens for advanced small cell lung cancer
Anticancer Research
|March 28, 2001
Summary
This study explored a new chemotherapy regimen for advanced small cell lung cancer, using dose intensification and sequential drug administration. The treatment showed acceptable toxicity and achieved objective responses in most patients, indicating feasibility for further research.
Area of Science:
- Oncology
- Medical Oncology
- Clinical Pharmacology
Background:
- Advanced small cell lung cancer (SCLC) necessitates effective treatment strategies.
- Optimizing chemotherapy delivery and dose intensity is crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the feasibility and toxicity of a novel, dose-intensified, sequential chemotherapy regimen for advanced SCLC.
- To assess the objective response rate and delivered dose intensity of the proposed regimen.
Main Methods:
- A sequential regimen combining cyclophosphamide, epidoxorubicin, and vincristine, followed by cisplatin and etoposide.
- Prophylactic use of granulocyte colony-stimulating factor (filgrastim) to support dose intensity and shorten treatment intervals.
- Assessment of delivered dose intensity, toxicity, and objective response in 16 patients.
Main Results:
- 11 out of 16 patients achieved >80% of the planned dose intensity.
- Acceptable toxicity profile with no life-threatening adverse events observed.
- Objective responses (partial or complete) were observed in 11 patients.
Conclusions:
- The novel sequential chemotherapy regimen is feasible for advanced SCLC.
- Dose intensification, supported by filgrastim, is achievable with acceptable toxicity.
- This regimen warrants further investigation in clinical studies for advanced SCLC.